Financial insights of BIXT

MyFinsight

For the quarter ending 2026-03-31.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Research and development	225,479	146,500*	-	102,500
General and administrative	213,974	413,986*	159,131	99,531
General and administrative affiliates	1,493,600	201,897*	336,874	22,048
Total operating expenses	1,933,053	762,383	496,005	224,079
Loss from operations	-1,933,053	-762,383*	-496,005	-224,079
Change in fair value (fv) of derivative	-73,136	-974,597.75*	264,796	307,402
Interest expense	35,729	34,363*	36,522	30,112
Interest expense affiliate	24,963	12,840*	10,759	15,265
Gain/loss of issuance	-	-	-	0
Amortization of intellectual property	2,108	1,426.5*	4,236	2,509
Debt discount amortization and issuance of warrants	-	-	-	0
Debt forgiveness	-	33,466.75*	-	-
Total other expenses	-135,936	-989,760.5*	213,279	259,516
Net loss before provision for income taxes	-2,068,989	-1,752,143.5	-282,726	35,437
Provision for income taxes	-	-	-	0
Net loss	-2,068,989	-1,752,143.5	-282,726	35,437
Net loss attributable to the non-controlling interest	-	-	-	0
Net loss attributable to bioxytran	-2,068,989	-1,752,143.5	-282,726	35,437

Basic EPS	-0.02	-0.018	0	0
Diluted EPS	-0.02	-0.018	0	0
Basic Average Shares	112,283,387	97,698,262	88,992,242	88,839,723
Diluted Average Shares	112,283,387	97,698,262	88,992,242	88,839,723